{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:53:16Z","timestamp":1790959996256,"version":"4.1.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003569","name":"ministry of food and drug safety","doi-asserted-by":"publisher","award":["21153MFDS602"],"award-info":[{"award-number":["21153MFDS602"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"korea health industry development institute","doi-asserted-by":"publisher","award":["HI19C1343"],"award-info":[{"award-number":["HI19C1343"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI19C1343"],"award-info":[{"award-number":["HI19C1343"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>While moderate-intensity statin therapy is recommended for primary prevention, statins may not be utilized at a recommended intensity due to dose-dependent adverse events, especially in an Asian population. However, evidence supporting the use of low-intensity statins in primary prevention is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We sought to compare clinical outcomes between a low-intensity statin plus ezetimibe and a moderate-intensity statin for primary prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This population-based retrospective cohort study used the Korean nationwide claims database (2002-2019). We included adults without atherosclerotic cardiovascular diseases who received moderate-intensity statins or low-intensity statins plus ezetimibe. The primary outcome was a composite of all-cause mortality, myocardial infarction, and ischemic stroke. The safety outcomes were liver and muscle injuries and new-onset diabetes mellitus (DM). We used standardized inverse probability of treatment weighting (sIPTW) and propensity score matching (PSM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the sIPTW model, 1717 and 36\u2009683 patients used a low-intensity statin plus ezetimibe and a moderate-intensity statin, respectively. In the PSM model, each group included 1687 patients. Compared with moderate-intensity statin use, low-intensity statin plus ezetimibe use showed similar risks of the primary outcome (hazard ratio [HR] = 0.92, 95% CI = 0.81-1.12 in sIPTW and HR = 1.16, 95% CI = 0.87-1.56 in PSM model). Low-intensity statin plus ezetimibe use was associated with decreased risks of liver and muscle injuries (subHR [sHR] = 0.84, 95% CI = 0.74-0.96 and sHR = 0.87, 95% CI = 0.77-0.97 in sIPTW; sHR = 0.84, 95% CI = 0.72, 0.96 and sHR = 0.82, 95% CI = 0.72-0.94 in PSM model, respectively). For new-onset DM and hospitalization of liver and muscle injuries, no difference was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Low-intensity statin plus ezetimibe may be an alternative to moderate-intensity statin for primary prevention. Our findings provide evidence on safety and efficacy of statin therapy in Asian population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241237781","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T08:07:47Z","timestamp":1710922067000},"page":"1193-1203","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-Intensity Statin Plus Ezetimibe Versus Moderate-Intensity Statin for Primary Prevention: A Population-Based Retrospective Cohort Study in Asian Population"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5489-827X","authenticated-orcid":false,"given":"Minji","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom-Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Ajou University, Suwon, Republic of Korea"},{"name":"Research Institute of Pharmaceutical Sciences and Technology, Ajou University, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhyang","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, College of Pharmacy, Ajou University, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaekyu","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"bibr1-10600280241237781","unstructured":"World Health Organization. Cardiovascular diseases (CVDs) fact sheet [Internet]. Accessed January 24, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"key":"bibr2-10600280241237781","unstructured":"World Health Organization.Ageing and health [Internet]. Accessed January 24, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health"},{"key":"bibr3-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133317.49796.0E"},{"key":"bibr4-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678"},{"key":"bibr5-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"bibr6-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac015"},{"key":"bibr7-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.02.011"},{"key":"bibr8-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"bibr9-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.02.099"},{"key":"bibr10-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00916-3"},{"key":"bibr11-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/18.1.84"},{"key":"bibr12-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv319"},{"key":"bibr13-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"bibr14-10600280241237781","unstructured":"Nau DP. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. Pharmacy Quality Alliance; 2012;6:25"},{"key":"bibr15-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1186\/s42444-019-0005-0"},{"key":"bibr16-10600280241237781","doi-asserted-by":"publisher","DOI":"10.2165\/0129784-200808060-00004"},{"key":"bibr17-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"bibr18-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2016.05.008"},{"key":"bibr19-10600280241237781","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0013"},{"key":"bibr20-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"key":"bibr21-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115101"},{"key":"bibr22-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07256-1"},{"key":"bibr23-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.07.016"},{"key":"bibr24-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.10.105"},{"key":"bibr25-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13985"},{"key":"bibr26-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000034044.95911.DC"},{"key":"bibr27-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e32833c1f16"},{"key":"bibr28-10600280241237781","doi-asserted-by":"publisher","DOI":"10.2174\/092986707779313381"},{"key":"bibr29-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181bfb1a2"},{"key":"bibr30-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.08.013"},{"key":"bibr31-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00289.x"},{"key":"bibr32-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011765"},{"key":"bibr33-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00965-x"},{"key":"bibr34-10600280241237781","unstructured":"FDA: Limit use of 80 mg Simvastatin. FDA Consumer Health Information [Internet]. Accessed January 24, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor"},{"key":"bibr35-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2211"},{"key":"bibr36-10600280241237781","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000073"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241237781","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241237781","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241237781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:37Z","timestamp":1777374817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241237781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/10600280241237781"],"URL":"https:\/\/doi.org\/10.1177\/10600280241237781","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}